Previous 10 | Next 10 |
CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO) PR Newswire MONMOUTH JUNCTION, N.J. , Dec. 20, 2021 /PRNewswire/ -- CytoSorbents Cor...
CytoSorbents to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and Jefferies London Healthcare Conference CytoSorbents to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and Jefferies Lo...
Cytosorbents (NASDAQ:CTSO): Q3 GAAP EPS of -$0.15 misses by $0.03. Revenue of $9.76M (-7.5% Y/Y) beats by $0.03M. Press Release For further details see: Cytosorbents EPS misses by $0.03, beats on revenue
CytoSorbents Reports Full Third Quarter 2021 Financial and Operational Results Third Quarter 2021 total revenue was $9.8 million, including product sales of $8.9 million. Core non-COVID-19 product sales increased 3% Y-Y to approximately $7.8 million. PR Newswire MO...
CytoSorbents Comments on REMOVE Study Presentation PR Newswire MONMOUTH JUNCTION, N.J. , Oct. 20, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery usin...
First Patient Enrolled in U.S. STAR-T Pivotal Trial Evaluating the DrugSorb-ATR™ Antithrombotic Removal System to Remove Ticagrelor During Cardiothoracic Surgery PR Newswire MONMOUTH JUNCTION, N.J. , Oct. 14, 2021 /PRNewswire/ -- CytoSorbents Corporati...
Wall Street saw choppy trading on Wednesday, with the Nasdaq and S&P 500 eventually eking out thin gains by the close. However, the late rally didn't save shares of credit card issuers, which saw weakness on signs of stepped-up competition in the space. American Express (NYSE:AXP), Synchr...
CytoSorbents Receives Full FDA Investigational Device Exemption (IDE) Approval to Begin U.S. STAR-D Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During Urgent Cardiothoracic Surgery The U.S. STAR-D and already recruiting STA...
CytoSorbents Provides Preliminary Third Quarter Business Update and Revised 2021 Product Revenue Guidance Preliminary third quarter 2021 total revenue was $9.7 million, including product sales of $8.9 million. Preliminary core non-COVID-19 product sales increased 4% Y-Y to appro...
Cytosorbents reports the results from their Endocarditis REMOVE trial at the EACTS (European Association for Cardio-Thoracic Surgery) conference. REMOVE, Cytosorbents' Endocarditis trial, failed to meet the primary and secondary end points. I look at the results and share my thoug...
News, Short Squeeze, Breakout and More Instantly...
CytoSorbents Corporation Company Name:
CTSO Stock Symbol:
NASDAQ Market:
CytoSorbents Corporation Website:
PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces that it has regained comp...
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, is proud to announce the launch of ...
PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces it will present...